Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 42Neoplasms 14Carcinoma, Hepatocellular 9Gastrointestinal Stromal Tumors 7Liver Neoplasms 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Colonic Neoplasms 3Carcinoma, Renal Cell 3Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Neoplasm Metastasis 2Lung Neoplasms 2Glioblastoma 2Esophageal Squamous Cell Carcinoma 2Astrocytoma 2Advanced Cancer 2Wilms Tumor 1Uterine Cervical Neoplasms 1Unresectable Locally Advanced or Metastatic Solid Tumors 1Stomach Neoplasms 1Spinocerebellar Degenerations 1Solid Malignant Tumors 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Renal Insufficiency 1Rectal Neoplasms 1Physician Education 1Pancreatic Neoplasms 1Neuroblastoma 1Melanoma 1

Interventions

Dexamethasone 4pomalidomide 2Azacitidine 2vinflunine 1trifluridine tipiracil drug combination 1trebananib 1safinamide 1sacubitril and valsartan sodium hydrate drug combination 1rubitecan 1ripretinib 1regorafenib 1pevonedistat 1pembrolizumab 1osimertinib 1mirabegron 1melflufen 1gallium 68 PSMA-11 1copanlisib 1carfilzomib 1belinostat 1belantamab mafodotin 1Zoledronic Acid 1Topotecan 1Tablets 1Sitagliptin Phosphate 1Pluvicto 1Paclitaxel 1Lenalidomide 1L-melphalanyl-p-L-fluorophenylalanine ethyl ester 1Gemcitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Renal Insufficiency × regorafenib × Clear all
NCT01853046 2017-02-20

Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment

Bayer

Phase 1 Completed
24 enrolled 30 charts

Neoplasms, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡